Indications & Uses
Angiodin is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage PCI/PTCA: IV Bolus dose of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h for duration of PCI procedure. Five minutes after bolus dose, obtain ACT and administer additional bolus of 0.3 mg/kg if indicated.HIT/HITTS: IV Bolus dose of 0.75 mg/kg, followed by a continuous infusion at a rate of 1.75 mg/kg/h for the duration of the procedure.Continuation of Therapy: IV Infusion may be continued for up to 4 h post-procedure as indicated. After 4 h, an additional IV infusion of 0.2 mg/kg/h for up to 20 h may be given if needed.Concomitant Therapy: Bivalirudin is intended for concurrent use with aspirin (300 to 325 mg/day).Renal Function Impairment: CrCl 30 to 50 mL/min: Administer infusion at rate of 1.75 mg/kg/h. CrCl less than 30 mL/min: Reduce infusion rate to 1 mg/kg/h. Hemodialysis: Reduce infusion rate to 0.25 mg/kg/h. No reduction in bolus dose needed.
Side Effects
Bleeding, Body as a Whole: fever,infection, sepsis; Cardiovascular: hypotension, syncope, vascular anomaly,ventricular fibrillation; Nervous: cerebral ischemia, confusion, facialparalysis; Respiratory: lung edema; Urogenital: kidney failure, oliguria.
Cautions & Contraindications
Warnings & Precautions
Bleeding Events: Although most bleeding associated with the use of Biva in PCI/PTCA occurs at the site of arterial puncture, hemorrhage can occur at any site. An unexplained fall in blood pressure or hematocrit should lead to serious consideration of a hemorrhagic event and cessation of Biva administration. Biva should be used with caution in patients with disease states associated with an increased risk of bleeding. Coronary Artery Brachytherapy: An increased risk of thrombus formation, including fatal outcomes, has been associated with the use of Biva in gamma brachytherapy. If a decision is made to use Biva during brachytherapy procedures, maintain meticulous catheter technique, with frequent aspiration and flushing, paying special attention to minimizing conditions of stasis within the catheter or vessels.
Contraindications
Bivalirudin should not be used in patients with active major bleeding or known hypersensitivity (including anaphylaxis) to bivalirudin or any of its components.